The present study suggests an intriguing possibility of using endothelin-1 and oxytocin, as well as their therapeutic analogs, as novel therapeutic targets for memory loss, such as that seen in Alzheimer's disease. Here, OXT is linked to early-onset autosomal dominant Alzheimer disease.